Prior to joining Seattle Genetics, Dr Waller was with Sonus Pharmaceuticals, where she served as senior vice president of regulatory affairs/quality assurance and clinical research until its merger with OncoGenex Pharmaceuticals.
Prior to Seattle Genetics, Mr Pawlowicz was senior vice president of human resources and administration at MedPointe Pharmaceuticals, a specialty pharmaceutical company.
Dr Drachman has been with Seattle Genetics since 2004, serving most recently as senior medical director.
Clay Siegall, president and CEO of Seattle Genetics, said: “Jonathan’s promotion reflects his dedication and the substantial drug development acumen he has demonstrated in his four years with the company. Our team is further strengthened by the additions of Elaine and Chris who have extensive experience in their respective fields.”